315 related articles for article (PubMed ID: 10477007)
21. Factors predicting for urinary incontinence after prostate brachytherapy.
McElveen TL; Waterman FM; Kim H; Dicker AP
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
[TBL] [Abstract][Full Text] [Related]
22. Brachytherapy in patients with small prostate glands.
Loblaw DA; Wallner K; Dibiase S; Russell K; Blasko J; Ellis W
Tech Urol; 2000 Jun; 6(2):64-9. PubMed ID: 10798802
[TBL] [Abstract][Full Text] [Related]
23. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: a phase 2 study.
Salem N; Simonian-Sauve M; Rosello R; Alzieu C; Gravis G; Maraninchi D; Bladou F
Radiother Oncol; 2003 Feb; 66(2):159-65. PubMed ID: 12648787
[TBL] [Abstract][Full Text] [Related]
24. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Murray B; Allen Z; Lief JH; Galbreath RW
Brachytherapy; 2004; 3(1):22-9. PubMed ID: 15110310
[TBL] [Abstract][Full Text] [Related]
25. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.
Zelefsky MJ; Hollister T; Raben A; Matthews S; Wallner KE
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1261-6. PubMed ID: 10889379
[TBL] [Abstract][Full Text] [Related]
26. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials.
Ghaly M; Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1288-93. PubMed ID: 12654439
[TBL] [Abstract][Full Text] [Related]
27. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Stock RG; Stone NN
Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
[TBL] [Abstract][Full Text] [Related]
28. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
[TBL] [Abstract][Full Text] [Related]
29. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.
Herstein A; Wallner K; Merrick G; Mitsuyama H; Armstrong J; True L; Cavanagh W; Butler W
Cancer J; 2005; 11(5):385-9. PubMed ID: 16259869
[TBL] [Abstract][Full Text] [Related]
30. Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate.
Stokes SH; Real JD; Adams PW; Clements JC; Wuertzer S; Kan W
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(2):337-41. PubMed ID: 9069305
[TBL] [Abstract][Full Text] [Related]
31. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
[TBL] [Abstract][Full Text] [Related]
32. Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?
Stone NN; Cesaretti JA; Rosenstein B; Stock RG
Brachytherapy; 2010; 9(2):114-8. PubMed ID: 19879812
[TBL] [Abstract][Full Text] [Related]
33. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
34. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma.
Dattoli M; Wallner K; Sorace R; Koval J; Cash J; Acosta R; Brown C; Etheridge J; Binder M; Brunelle R; Kirwan N; Sanchez S; Stein D; Wasserman S
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(5):875-9. PubMed ID: 8751395
[TBL] [Abstract][Full Text] [Related]
35. Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.
Krauss DJ; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Gustafson GS
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):98-106. PubMed ID: 27979460
[TBL] [Abstract][Full Text] [Related]
36. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer.
Prestidge BR; Hoak DC; Grimm PD; Ragde H; Cavanagh W; Blasko JC
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):31-9. PubMed ID: 9054874
[TBL] [Abstract][Full Text] [Related]
37. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
38. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
39. Rectal dosimetric analysis following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Lief JH; Walbert HL; Blatt HJ
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):1021-7. PubMed ID: 10192350
[TBL] [Abstract][Full Text] [Related]
40. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity.
Merrick GS; Butler WM; Wallner K; Galbreath RW; Anderson RL; Kurko BS; Lief JH
Urology; 2002 Jul; 60(1):104-8. PubMed ID: 12100933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
